Septerna (NASDAQ:SEPN) Shares Down 4.3% – Time to Sell?

Septerna, Inc. (NASDAQ:SEPN)’s share price traded down 4.3% on Wednesday . The company traded as low as $15.51 and last traded at $15.32. 23,687 shares traded hands during mid-day trading, a decline of 87% from the average session volume of 187,526 shares. The stock had previously closed at $16.01.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Cantor Fitzgerald assumed coverage on shares of Septerna in a research note on Tuesday, November 19th. They issued an “overweight” rating and a $50.00 price objective for the company. TD Cowen started coverage on shares of Septerna in a research report on Tuesday, November 19th. They set a “buy” rating for the company. JPMorgan Chase & Co. started coverage on shares of Septerna in a research report on Tuesday, November 19th. They set an “overweight” rating and a $38.00 price target for the company. Finally, Wells Fargo & Company started coverage on shares of Septerna in a research report on Tuesday, November 19th. They set an “overweight” rating and a $43.00 price target for the company.

Septerna Trading Down 4.0 %

The company has a fifty day simple moving average of $22.02.

Institutional Trading of Septerna

A hedge fund recently bought a new stake in Septerna stock. SG Americas Securities LLC purchased a new position in Septerna, Inc. (NASDAQ:SEPN) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 8,095 shares of the company’s stock, valued at approximately $185,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.